Featured Research

from universities, journals, and other organizations

Study Of New Treatment For Short Stature Underway At Rush University Medical Center

Date:
September 20, 2005
Source:
Rush University Medical Center
Summary:
Rush University Medical Center is participating in a clinical trial to evaluate the potential benefit of the first major innovation in 20 years for the treatment of growth failure. The drug, called Increlex, was approved by the FDA August 31 for the most severe form of short stature due to a deficiency of Insulin-like Growth Factor-1 (IGF-1). Ongoing trials will determine if the drug may be used for less severe growth disease.

CHICAGO -- Rush University Medical Center is participating ina clinical trial to evaluate the potential benefit of the first majorinnovation in 20 years for the treatment of growth failure. The drug,called Increlex, was approved by the FDA August 31 for the most severeform of short stature due to a deficiency of Insulin-like GrowthFactor-1 (IGF-1). Ongoing trials will determine if the drug may be usedfor less severe growth disease.

Related Articles


Insulin-like Growth Factor-1(IGF-1) is the proximate hormone necessary for statural growth and mustbe present in order for children's bones, cartilage and organs to grownormally. In healthy individuals, growth hormone is secreted into thebloodstream by the pituitary gland and binds to growth hormonereceptors on liver and other cells, where it stimulates the cellularproduction and secretion of IGF-1 into the bloodstream.

"Fordecades, the only available drug treatment for short stature has beenshots of growth hormone. However, patients who are deficient in IGF-1and resistant to the effects of growth hormone do not respond well, ifat all, to the shots," said Dr. Richard Levy, a pediatricendocrinologist at Rush. "Instead of using growth hormone to stimulatethe production of IGF-1, the goal is to replace the IGF-1 directly."

Increlexis a genetically engineered copy of IGF-1. The purified protein hasbeen shown to be structurally and functionally identical to naturalhuman IGF-1. It is injected daily before a meal to provide the catalystthe body needs to grow.

The FDA's approval of Increlex is basedon clinical trial data from 71 patients. Data reported at the 2004Annual Meeting of the Endocrine Society demonstrated a statisticallysignificant increase in growth rate over an eight-year period inresponse to Increlex therapy. Compared to pre-treatment growthpatterns, on average, children gained an additional inch per year foreach year of therapy over the course of eight years. In addition, ananalysis of safety in the study concluded that long-term treatmentappears to be well tolerated and has an acceptable safety profile. Themost common adverse events were hypoglycemia, lipohypertrophy andtonsillar hypertrophy.

Primary IGFD afflicts an estimated 30,000children evaluated for short stature in the United States. A child withshort stature is defined as being shorter than 97.5 percent of allchildren the same age and gender. If untreated, Primary IGFD may lead,in children and adults, to a range of other metabolic disorders,including lipid abnormalities, decreased bone density, obesity, andinsulin resistance.

Increlex is manufactured by Tercica, Inc., abiopharmaceutical company focused on the development andcommercialization of products to improve endocrine health. For furtherinformation on Tercica please visit www.tercica.com.

For more information about Pediatric Endocrinology services at Rush, please call Dr. Levy's office at 312-942-8989.


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "Study Of New Treatment For Short Stature Underway At Rush University Medical Center." ScienceDaily. ScienceDaily, 20 September 2005. <www.sciencedaily.com/releases/2005/09/050920081239.htm>.
Rush University Medical Center. (2005, September 20). Study Of New Treatment For Short Stature Underway At Rush University Medical Center. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2005/09/050920081239.htm
Rush University Medical Center. "Study Of New Treatment For Short Stature Underway At Rush University Medical Center." ScienceDaily. www.sciencedaily.com/releases/2005/09/050920081239.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins